As part of cooperation with the World Health Organization (WHO), the specialists of Almazov Centre contributed to the preparation of three new Health Evidence Network synthesis reports, supported by the WHO Regional Office for Europe.
The first report (What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? Second edition. World Health Organization. Regional Office for Europe) is an updated review of a report on the effectiveness of population-level screening programmes for reducing the burden of CVD published in 2021. It includes an updated literature search and a more comprehensive investigation of country-level specific screening programmes. This updated review includes final results from two studies which were ongoing in 2021. It also identified 10 new studies, but none of these met the inclusion criteria. It shows that screening for CVD risk factors does not lower CVD morbidity and mortality or health-care expenses. Screening for preclinical CVD slightly reduces mortality and negative outcomes related to abdominal aortic aneurysm; however, the results may be outdated owing to a decline in smoking and improved treatment. Screening for atrial fibrillation or screening for a mixture of risk factors and preclinical CVD has a marginal effect on morbidity and mortality.
- Full report (English)
- Summary report (English)
- Summary report(Russian)
The second report (What is the effect of population-level screening of asymptomatic adults for type 2 diabetes mellitus or intermediate hyperglycaemia on health outcomes? World Health Organization. Regional Office for Europe) focused on the effect of population-level screening of asymptomatic adults for type 2 diabetes mellitus or intermediate hyperglycaemia on health outcomes. The report states that there is currently no evidence that screening for type 2 diabetes mellitus or intermediate hyperglycaemia reduces morbidity or mortality.
- Full report (English)
- Summary report (English)
- Summary report(Russian)
The third report (Can type 2 diabetes and its associated complications be prevented or delayed in people with intermediate hyperglycaemia? World Health Organization. Regional Office for Europe) assessed the effects of interventions for people with intermediate hyperglycaemia. Results from randomized controlled trials indicate that the risk of developing type 2 diabetes in people with intermediate hyperglycaemia is reduced by lifestyle and some pharmacological interventions. Most of the available evidence did not find a difference in mortality for either pharmacological or lifestyle interventions. However, the follow-up periods may have been too short for health outcomes to have emerged.
- Full report (English)
- Summary report (English)
- Summary report(Russian)